Eastern Equine Encephalitis – Pipeline Review, H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Eastern Equine Encephalitis – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

The publisher’s latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis – Pipeline Review, H1 2020, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the Eastern equine encephalitis virus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

The publisher’s Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

Key Topics Covered:

• Introduction
• Report Coverage
• Eastern Equine Encephalitis – Overview
• Eastern Equine Encephalitis – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Eastern Equine Encephalitis – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Eastern Equine Encephalitis – Companies Involved in Therapeutics Development
• Bavarian Nordic A/S
• Profectus BioSciences Inc
• Ridgeback Biotherapeutics LP
• Eastern Equine Encephalitis – Drug Profiles
• EIDD-2801 – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• encephalitis (trivalent,virus like particle) vaccine – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• equine encephalitis (trivalent) vaccine – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• equine encephalitis vaccine – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Small Molecule for Eastern Equine Encephalitis and Venezuelan Equine Encephalitis – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Small Molecule to Inhibit Myd88 for Infectious Diseases, Inflammation, Septic Shock and Toxic Shock – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• TSI-GSD-104 – Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Eastern Equine Encephalitis – Dormant Projects
• Eastern Equine Encephalitis – Product Development Milestones
• Featured News & Press Releases
• Apr 18, 2019: UofL researcher developing drug to treat emerging encephalitis viruses
• Jan 24, 2019: Bavarian Nordic advances development of equine encephalitis virus vaccine
• Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact
• Disclaimer

Companies Mentioned

• Bavarian Nordic A/S
• Profectus BioSciences Inc
• Ridgeback Biotherapeutics LP

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vfmeiq

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900